Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period
Brief Summary: This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide.

Trial has the following trial periods: A 20-week randomised, double-blind, placebo-controlled, six-armed parallel-group, multi-centre, multinational trial with an open label orlistat comparator arm followed by an 84 week extension period.


Options:
A: Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68); Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68); Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Liraglutide Placebo, no Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Liraglutide 3.0mg, Pre-diabetes; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide Placebo, Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), Liraglutide Placebo, no Pre-diabetes | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg, Pre-diabetes | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide Placebo, Pre-diabetes
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lira placebo/Lira 2.4 mg/Lira 3.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Lira 1.2 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Lira 1.8 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Lira 2.4 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Orlistat; Type: ACTIVE_COMPARATOR; Interventions: Drug: orlistat | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 mg/Lira 3.0 mg, Lira 1.8 mg/Lira 3.0 mg, Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg | Intervention Type: DRUG; Name: orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira placebo/Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg
D: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin

Answer: C